Verona Pharma Plc (LON:VRP) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is GBX 130 ($1.76).
A number of research firms have recently issued reports on VRP. restated a “buy” rating on shares of Verona Pharma in a research report on Tuesday, November 7th. N+1 Singer restated a “buy” rating on shares of Verona Pharma in a research report on Tuesday, November 7th. Finally, Jefferies Group restated a “buy” rating and issued a GBX 250 ($3.39) price target on shares of Verona Pharma in a research report on Wednesday, November 8th.
In other Verona Pharma news, insider David Ebsworth acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average cost of GBX 107 ($1.45) per share, for a total transaction of £10,700 ($14,510.44).
Shares of Verona Pharma (LON:VRP) opened at GBX 117.58 ($1.59) on Monday. Verona Pharma has a 52-week low of GBX 100 ($1.36) and a 52-week high of GBX 189 ($2.56).
ILLEGAL ACTIVITY WARNING: “Verona Pharma Plc (VRP) Given Consensus Recommendation of “Buy” by Brokerages” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/29/verona-pharma-plc-vrp-given-consensus-recommendation-of-buy-by-brokerages.html.
Verona Pharma Company Profile
Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.